Bicycle Therapeutics plc (BCYC) News
Filter BCYC News Items
BCYC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BCYC News Highlights
- For BCYC, its 30 day story count is now at 2.
- Over the past 14 days, the trend for BCYC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest BCYC News From Around the Web
Below are the latest news stories about BICYCLE THERAPEUTICS PLC that investors may wish to consider to help them evaluate BCYC as an investment opportunity.
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D DayCAMBRIDGE, England & BOSTON, December 14, 2023--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, is today hosting a Research & Development (R&D) Day for investors and analysts in New York to provide clinical updates for BT8009, BT7480 and BT5528, and an overview of the company’s strategy and pipeline opportunities. The company will also highlight the broad capabi |
Bicycle Therapeutics to Host R&D Day on December 14CAMBRIDGE, England & BOSTON, November 30, 2023--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will host its first Research and Development (R&D) Day on Thursday, December 14. The event will take place in New York City from 8 a.m. to 12 p.m. Eastern Time and will be simultaneously webcast. |
Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Just Trimmed Their Revenue Forecasts By 13%One thing we could say about the analysts on Bicycle Therapeutics plc ( NASDAQ:BCYC ) - they aren't optimistic, having... |
Bicycle Therapeutics PLC (BCYC) Reports Q3 2023 Financial Results and Upcoming R&D DayCompany's cash and cash equivalents stand at $572.1 million as of September 30, 2023 |
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D DayCAMBRIDGE, England & BOSTON, November 02, 2023--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates. |
‘The Stage Is Set for a Rally’: Canaccord Sees up to 290% Upside for These 3 StocksThe last few months have been tough for investors, as stocks have mostly been falling since mid-summer. To wit, the S&P 500, which peaked at the end of July, is down close to 8% from that high. The headwinds behind these losses are well-known: stubborn inflation, the Fed’s persistence in sticking to a high-interest-rate, tight-money policy in response, a worsening geopolitical situation and related rising oil prices, increasing bond yields, and the uncertainty of an upcoming election; it would b |
Bicycle Therapeutics to Participate in Upcoming Investor ConferencesCAMBRIDGE, England & BOSTON, October 30, 2023--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in November: |
Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder CancerCAMBRIDGE, England & BOSTON, October 19, 2023--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that BT8009, the company’s lead investigational therapy in development to treat metastatic bladder (urothelial) cancer, has been selected to participate in the Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program re |
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive DirectorEDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director. Based in the UK and CEO of Cambridge, UK/Cambridge, US based, Bicycle Therapeutics (NASDAQ: BCYC), Kevin brings two decades of biotech and pharma experience to Macomics. In addition to his seat on Bicycle’s board of directors, he is also a non-executive director of Alchemab Thera |
An excellent week for Bicycle Therapeutics plc's (NASDAQ:BCYC) institutional owners who own 64% as one-year returns inch higherKey Insights Given the large stake in the stock by institutions, Bicycle Therapeutics' stock price might be vulnerable... |